



Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a

PTO/SB/21 (6-98)
Approved for use through 09/30/2000, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

4

Application Number

09/768,917

Filing Date

January 24, 2001

First Named Inventor

Vicari et al.

Group Art Unit

To be Assigned

Examiner Name

To be Assigned

Attorney Docket Number

SF0896K

ENCLOSURES (check all that apply)

- Fee Transmittal Form
- Fee Attached
- Amendment / Response
 - After Final
 - Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement
- Certified Copy of Priority Document(s)
- Response to Missing Parts/ Incomplete Application
- Response to Missing Parts under 37 CFR 1.52 or 1.53

- Assignment Papers (for an Application)
- Drawing(s)
- Licensing-related Papers
- Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, Revocation Change of Correspondence Address
- Terminal Disclaimer
- Small Entity Statement
- Request for Refund

- After Allowance Communication to Group
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Additional Enclosure(s) (please identify below)

References: 13
Form PTO 1449 - 1 pg.
PostCard Receipt

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual name

Jaye P. McLaughlin, Registration No. 41,211

Signature

Date

July 24, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date July 24, 2001

Typed or printed name


Jaye P. McLaughlin, Registration No. 41,211

Signature

Date

July 24, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Vicari, *et al.*

Serial No.: 09/768,917

Filed: January 24, 2001

For: CHEMOKINES AS ADJUVANTS
OF IMMUNE RESPONSE

: Examiner: To be assigned

: Group Art Unit: To be assigned

: Atty. Docket No.: SF0896K

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the documents, as listed below and on the accompanying form PTO 1449, be considered and made of record in the above-identified application. A copy of each document is attached.

Foreign Patent Document

WO 98/01557
WO 98/14573
WO 97/31098
WO 95/17092
WO 96/34891
WO 94/21277
WO 97/19696
WO 97/41831
WO 94/07521
WO 94/13321

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on

July 24, 2001

Date of Deposit

Jaye McLaughlin

Registered Representative

Signature & Date

Other Documents

Fioretti et al, 1998, "Reduced Tumorigenicity and Augmented Leukocyte Infiltration After Monocyte Chemotactic Protein-3 Gene Transfer" *J. Immunol.* **161**(1):342-346.

Dematos et al., 1998, "Pulsing of Dendritic Cells with Cell Lysates from either B16 Melanoma or MCA-106 Fibrosarcoma Yields Equally Effective Vaccines Against B16 Tumors in Mice" *J. Surg. Oncol.* **68**(2):79-91.

Vicari et al., 2000, "Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms" *J. Immunol.* **165**:1992-2000.

Respectfully submitted,



Jaye McLaughlin
Attorney/Agent for Applicant(s)
Registration No.: 41,211
Telephone No.: (908) 298-4299

SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
Date: July 24, 2001

PTO-1449
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

JUL 28 2006

Sheet 1 of 1

ATTY. DOCKET NO.:	SF0896K	SERIAL NO.:	09/768,917
APPLICANT:		Vicari, et al.	
FILING DATE:		January 24, 2001	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
						YES
AE	WO98/01557	1/15/98				
AF	WO98/14573	4/9/98				
AG	WO97/31098	8/28/97				
AI	WO95/17092	6/29/95				
AK	WO96/34891	11/7/96				
AL	WO94/21277	6/29/94				
AM	WO97/19696	6/5/97				
AN	WO97/41831	11/13/97				
AO	WO94/07521	4/14/94				
AP	WO94/13321	6/23/94				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	Fioretti et al., "Reduced Tumorigenicity and Augmented Leukocyte Infiltration After Monocyte Chemotactic Protein-3 Gene Transfer" <i>J. Immunol.</i> 161 (1):342-346.
AR	Dematos et al., 1998, "Pulsing of Dendritic Cells with Cell Lysates from either B16 melanoma or MCA-106 Fibrosarcoma Yields Equally Effective Vaccines Against B16 Tumors in Mice" <i>J Surg. Oncol.</i> 68 (2):79-91.
AS	Vicari et al., 2000, "Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms" <i>J Immunol.</i> 165 :1992-2000.
AT	
AU	
AV	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



JUL 28 2006 Express Mail Label:

EV 533176825 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): VICARI, Alain P

Group Art Unit: 1633

Application No.: 09/768917

Examiner: Anne Marie Sabrina Wehbe

Filed: 01/24/2001

Atty. Docket No. : SF0896KUS

For: CHEMOKINES AS ADJUVANTS OF IMMUNE RESPONSE

X

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop: Amendment
Sir:

(a) Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the documents listed on the accompanying Forms PTO/SB/08a & 08b be considered and made of record in the above-identified patent application. Other than cited U.S. patents and published patent applications, copy(ies) of these documents are enclosed were filed in related U.S. Application No(s) _____ filed _____ respectively. Since the Examiner is believed to have ready access to the cited U.S. patents and published patent applications, copies of these documents are not herewith transmitted, but will be provided upon request.

(b) No fee is believed to be due because:

- This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; **or**
- This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; **or**
- This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); **or**
- This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c) This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:

- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

08/01/2006 HDESTA1 00000086 190365 09768917

01 FC:1806 180.00 DA

- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **or**
- The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

(d) This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and:


- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **and**
- The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case.

Dated: July 28, 2006
Schering-Plough Corporation
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

By:

Respectfully submitted,


Grant E. Reed
Reg. No.: 47,264
Attorney of Record
Telephone No.: 908-298-5067

